Advertisement
MarketWatch

Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales

Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

M

Source

MarketWatch

Read full article at MarketWatch

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement